Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis

Journal of Infectious Diseases

Volumn 175, Issue 6, 1997, Pages 1477-1479

  Murray, Henry W ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HOST RESISTANCE; INTRAPERITONEAL DRUG ADMINISTRATION; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

EID: 0030911399     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516482     Document Type: Article

References (16)

1. Murray HW, Hariprashad J. Interleukin-12 is effective treatment for an established systemic intracellular infection: experimental visceral letshmaniasis. J Exp Med 1995;181:387-91.
2. Squires KE, Schreiber RD, McElrath MJ, Rubin BY, Anderson SL, Murray HW. Experimental visceral leishmaniasis: role of endogenous interferon-γ in host defense and tissue granulomatous response. J Immunol 1989;143:4244-9.
3. Murray HW. Effect of continuous administration of interferon-γ in experimental visceral leishmaniasis. J Infect Dis 1990;161:992-4.
4. Brunda M. Interleukin 12. J Leukoc Biol 1994;55:280-8.
5. Locksley RM. Interleukin 12 in host defense against microbial pathogens. Proc Natl Acad Sci USA 1993;90:5879-81.
6. Scott P. IL-12: initiation cytokine for cell-mediated immunity. Science 1993;260:496-7.
7. Trinchieri G. Interleukin 12: a proinflammatory cytokine with immunoregulatory functions that bridges innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-62.
8. Scharton-Kersten T, Afonso L, Wysocka M, Trinchieri G, Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol 1995;154: 5320-5.
9. + T cells to enhance priming for IFN-γ production and diminishes IL-4 inhibition of such priming. Proc Natl Acad Sci USA 1993;90: 10188-92.
10. Heinzel FP, Rerko RM, Ahmed F, Pearlman E. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J Immunol 1995;155:730-9.
11. Sypek J, Chung C, Mayor S, et al. Resolution of cutaneous leishmaniasis: IL-12 initiates a protective T helper type 1 immune response. J Exp Med 1993;177:1797-802.
12. Miralles GD, Stoeckle MY, McDermott DF, Finkelman FD, Murray HW. Induction of Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun 1994;62:1058-63.
13. McElrath J, Murray HW, Cohn ZA. The dynamics of granuloma formation in experimental visceral leishmaniasis. J Exp Med 1988;167:1927-37.
14. Murray HW, Stern JJ, Weite K, Rubin BY, Carriero SM, Nathan CF. Experimental visceral leishmaniasis: production of interleukin-2 and interferon-γ, tissue immune reaction, and response to treatment with interleukin-2 and interferon-γ. J Immunol 1987;138:2290-6.
15. Murray HW, Hariprashad J, Aguero B, Arakawa T, Yeganegi H. Intracellular antimicrobial response of the T cell-deficient host to cytokine therapy: effect of interferon-γ in experimental visceral leishmaniasis in nude mice. J Infect Dis 1995;171:1309-13.
16. Mattner F, Magram J, Ferrante J, et al. Genetically resistant mice lacking interleukin-12 are susceptible to Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996;26:1553-9.